Efficacy and safety of CT guided pudendal nerve catheter retention with discontinuous block for pudendal neuralgia: a prospective randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030245

Enrollment

Unknown

Registered

2020-02-26

Start date

2020-02-24

Completion date

Unknown

Last updated

2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pudendal neuralgia

Interventions

experimental group:CT guided pudendal nerve catheter retention with discontinuous block

control group:Single pudendal nerve block

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Comply with the basic criteria of "the Nantes criteria" proposed by Labat et al. In 2008 (the first 4): Pain in the anatomical territory of the pudendal nerve; Pain aggravated by sitting; No nocturnal waking due to pain; There is no objective sensory loss on examination; 2. Medical history is more than 6 months and less than 5 years; 3. Pain cannot be relieved after oral medication, VAS > 3 points; 4. Voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Meets the Nantes criteria exclusion criteria: Pain is limited to the coccyx, glutes, pubis, or lower abdomen (no pain at the innervated area of the vagina); itching; only paroxysmal pain; presence Abnormal imaging studies (MRI, CT or other) that can explain pain; 2. Perineal pain caused by diseases of the urinary and reproductive systems; 3. Perineal pain due to perianal and anorectal diseases; 4. Perineal pain caused by pelvic organ damage, tumor and nerve compression at the lumbar level confirmed by auxiliary examination (such as cauda equina syndrome, sacroiliac joint dysfunction, etc.); 5. Perineal pain due to infection (such as postherpetic pudendal neuralgia); 6. Have done related nerve block therapy, systemic or local corticosteroids medication history within 6 months; 7. Contraindications associated with ozone or corticosteroids medication, such as hyperthyroidism, G6PD deficiency, and adrenal hyperfunction; 8. People with abnormal blood coagulation; 9. People with cognitive or speech impairments; those who cannot complete the questionnaire; 10. Pregnant and lactating patients; 11. Patients with severe organic diseases such as heart, brain and lung.

Design outcomes

Primary

Measure	Time frame
visual analogue scale;	—

Countries

China

Contacts

Public ContactLiu Fang

Beijing Tsinghua Changgung Hospital

aroma06@163.com+86 13391623362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026